AMSTERDAM (Reuters) -Biotechnology firm Galapagos said on Tuesday it would wind down its cell therapy business after attempts to sell it were unsuccessful, affecting 365 jobs in Europe, China and the U.S.
The Amsterdam-listed company said it had received several non-binding offers since it began mulling options for its cell therapy business in May, but had concluded that none of those were viable proposals.
Galapagos said it now made more sense to gradually end the cell therapy business and use the capital to build a pipeline of new therapies.
Shares in the company were down 14% in early trading after its announcement.
(Reporting by Bart Meijer; Editing by Jan Harvey)
